Xigris (Drotrecogin alfa) is not an antibiotic but is approved for the specific indication of sepsis because of its anticoagulant properties.
Xigris (Drotrecogin alfa) is a drug approved by the Food and Drug Administration for the reduction of mortality in adult patients with severe sepsis who have a high risk of death. Xigris (Drotrecogin alfa) is placed under the class of serine proteases and it has anticoagulant, anti-thrombotic, anti-inflammatory, and profibrinolytic properties.
Answer:
The correct answer is A the compound is a competitive inhibitor
Explanation:
Competitive inhibitor competes with the substrate to bind to the active site of the target enzyme and after binding to the active site the inhibitor slow down or stop the reaction catalyzed by that enzyme.
Competitive inhibitor basically effects the Km value of the enzyme thus decreasing the activity of the later.
Increasing the substrate concentration displace the inhibitor from the enzyme"s active site thus reducing the inhibitory effects of the later thus increasing the activity of the enzyme.
Answer:
C) OXIDATION
Explanation:
Oxidation is the reaction of a substance with oxygen. When a rock reacts with oxygen, it forms iron oxide, which weakens the rock.
Answer:
where is the diagram
Explanation:
<h2>MARK ME BRAINLIEST PLZZZZZZZZZZZZZZZZZZZZZzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz</h2>
Answer:
See Explanation
Explanation:
We define antibiotic susceptibility testing as an evaluation of the ability of antibiotics to inhibit bacterial growth. This test is necessary because certain bacteria may have developed resistance to certain antibiotics.
Hence, if the antibiotic susceptibility testing result of Staphylococcus aureus showed absence of growth on the zones of penicillin, ampicillin, tetracycline and chloramphenicol disk, then it implies that these antibiotics are all largely effective against Staphylococcus aureus and could be used for treatment of Staphylococcus aureus infection.
